Maristella Donato

Dr. Maristella Donato

University of Padova
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in Atherosclerosis
Verified
Journal Article
Closed access
MLMaria Giovanna Lupo
Maria Giovanna Lupo
ABAlessandro Bressan
Alessandro Bressan
MDMaristella Donato
Maristella Donato
PCPaola Canzano
Paola Canzano
MCMarina Camera
Marina Camera
Nicola FerriNicola Ferri
Nicola Ferri

Verified
Journal Article
Open access
PDF file
MDMaristella Donato
Maristella Donato
Nicola FerriNicola Ferri
Nicola Ferri
MLMaria Giovanna Lupo
Maria Giovanna Lupo
EFElisabetta Faggin
Elisabetta Faggin
MRMarcello Rattazzi
Marcello Rattazzi
Calcific aortic valve stenosis (CAVS), the most common heart valve disease, is characterized by the slow progressive fibro-calcific remodeling of the valve leaflets, leading to progressive obstruction to the blood flow. CAVS is an increasing health care burden and the development of an effective medical treatment is a major medical need. To date, no effective pharmacological therapies have proven to halt or delay its progression to the severe symptomatic stage and aortic valve replacement represents the only available option to improve clinical outcomes and to increase survival. In the present report, the current knowledge and latest advances in the medical management of patients with CAVS are summarized, placing emphasis on lipid-lowering agents, vasoactive drugs, and anti-calcific treatments. In addition, novel potential therapeutic targets recently identified and currently under investigation are reported.

1 April 2020 in Atherosclerosis
Verified
Journal Article
Closed access
MRMarcello Rattazzi
Marcello Rattazzi
MDMaristella Donato
Maristella Donato
EBElisa Bertacco
Elisa Bertacco
RMRenato Millioni
Renato Millioni
CFCinzia Franchin
Cinzia Franchin
GAGiorgio Arrigoni
Giorgio Arrigoni

28 July 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MDMaristella Donato
Maristella Donato
EFElisabetta Faggin
Elisabetta Faggin
FCFrancesco Cinetto
Francesco Cinetto
CFCarla Felice
Carla Felice
MLMaria Giovanna Lupo
Maria Giovanna Lupo
MRMarcello Rattazzi
Marcello Rattazzi
Cardiovascular calcification is the ectopic deposition of calcium-phosphate crystals within the arterial wall and the aortic valve leaflets. This pathological process leads to increased vascular stiffness, reduced arterial elasticity, and aortic valve stenosis, increasing the risk of cardiovascular diseases. Although cardiovascular calcification is an increasing health care burden, to date no medical therapies have been approved for treating or preventing it. Considering the current lack of therapeutic strategies and the increasing prevalence of cardiovascular calcification, the investigation of some nutraceuticals to prevent this pathological condition has become prevalent in recent years. Recent preclinical and clinical studies evaluated the potential anti-calcific role of nutraceuticals (including magnesium, zinc, iron, vitamin K, and phytate) in the progression of vascular calcification, providing evidence for their dietary supplementation, especially in high-risk populations. The present review summarizes the current knowledge and latest advances for nutraceuticals with the most relevant preclinical and clinical data, including magnesium, zinc, iron, vitamin K, and phytate. Their supplementation might be recommended as a cost-effective strategy to avoid nutritional deficiency and to prevent or treat cardiovascular calcification. However, the optimal dose of nutraceuticals has not been identified and large interventional trials are warranted to support their protective effects on cardiovascular disease.

17 April 2024 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
CGCecilia M. Giachelli
Cecilia M. Giachelli
MDMaristella Donato
Maristella Donato
MSMarta Scatena
Marta Scatena
This editorial refers to ‘Smooth muscle cell-specific MMP-3 deletion reduces osteogenic transformation and medial artery calcification’, by Y. Xie et al.,https://doi.org/10.1093/cvr/cvae035.